MRTX1133 is definitely an extremely strong and selective KRASG12D inhibitor. It optimally fills the switch II pocket and extends a few substituents to favorably interact with the protein. The K And clinical trials of mix therapy with KRAS G12C inhibitors and immune checkpoint inhibitors are